Geode Capital Management LLC Boosts Stock Position in FibroGen, Inc. (NASDAQ:FGEN)

Geode Capital Management LLC raised its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 3.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,083,521 shares of the biopharmaceutical company’s stock after acquiring an additional 32,884 shares during the quarter. Geode Capital Management LLC’s holdings in FibroGen were worth $433,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. AQR Capital Management LLC lifted its stake in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 769,586 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of FibroGen in the 3rd quarter valued at $307,000. XTX Topco Ltd purchased a new position in shares of FibroGen in the 2nd quarter valued at $424,000. Cubist Systematic Strategies LLC grew its position in shares of FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of FibroGen during the second quarter worth about $145,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on FGEN. StockNews.com began coverage on FibroGen in a research report on Wednesday, January 1st. They set a “hold” rating on the stock. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th. Finally, William Blair reissued a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Price Performance

FibroGen stock opened at $0.62 on Monday. The business has a 50 day simple moving average of $0.42 and a 200-day simple moving average of $0.50. FibroGen, Inc. has a 12 month low of $0.18 and a 12 month high of $2.93. The stock has a market capitalization of $62.07 million, a PE ratio of -0.50 and a beta of 0.75.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the previous year, the company posted ($0.52) EPS. As a group, equities research analysts anticipate that FibroGen, Inc. will post -0.86 EPS for the current year.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.